CytRx Corporation (NASDAQ: CYTR) and Editas Medicine (NASDAQ:EDIT) are both small-cap biotechnology & medical research – nec companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.
Institutional and Insider Ownership
7.8% of CytRx Corporation shares are held by institutional investors. Comparatively, 70.5% of Editas Medicine shares are held by institutional investors. 5.3% of CytRx Corporation shares are held by insiders. Comparatively, 19.4% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This is a summary of current ratings and target prices for CytRx Corporation and Editas Medicine, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
CytRx Corporation presently has a consensus price target of $21.00, suggesting a potential upside of 950.00%. Editas Medicine has a consensus price target of $27.00, suggesting a potential upside of 10.75%. Given CytRx Corporation’s stronger consensus rating and higher probable upside, equities research analysts plainly believe CytRx Corporation is more favorable than Editas Medicine.
Earnings and Valuation
This table compares CytRx Corporation and Editas Medicine’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|CytRx Corporation||$200,000.00||276.40||-$50.76 million||($2.84)||-0.70|
|Editas Medicine||$6.05 million||169.73||-$97.18 million||($3.24)||-7.52|
CytRx Corporation has higher revenue, but lower earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than CytRx Corporation, indicating that it is currently the more affordable of the two stocks.
This table compares CytRx Corporation and Editas Medicine’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
About Editas Medicine
Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).
Receive News & Ratings for CytRx Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx Corporation and related companies with MarketBeat.com's FREE daily email newsletter.